Moderate to Severe Atopic Dermatitis: A Crowded Pipeline Still Chasing the Durable Cure - Emerging Therapy, Unmet Needs and TPP Insights Across 8MM | Thelansis

Atopic dermatitis (AD) has moved from a "steroid-and-moisturizer" condition to one of dermatology's most competitive biologic battlegrounds. Yet for the moderate-to-severe segment, the question executives are really asking isn't "how many drugs are coming?" It's "which ones will actually change the standard of care, and where is the next differentiated asset going to come from?"
Here's a grounded look at where the market stands, what's still missing, and what a winning Target Product Profile (TPP) needs to look like.

Thelansis' Moderate to Severe Atopic Dermatitis - Emerging Therapy, Unmet Needs & TPP Insights - 2026 examines these evolving trends across the development landscape, helping stakeholders assess future opportunities with greater confidence. Explore the full scope and download a sample: https://thelansis.com/reports/moderate-to-severe-atopic-dermatitis-emerging-therapy-with-unmet-needs-and-tpp-insights/

Market Context: A Growing Burden, A Crowding Field
Atopic dermatitis remains one of the most prevalent chronic inflammatory skin diseases globally, with well over a hundred million people affected worldwide. The moderate-to-severe subset, smaller in number but disproportionately burdensome in cost, quality-of-life impact, and treatment complexity, is where nearly all commercial and pipeline attention is now concentrated.
• The IL-4/IL-13 axis, once considered the sole domain of dupilumab, is now shared by lebrikizumab and tralokinumab, with newer entrants such as nemolizumab (targeting IL-31) further fragmenting the biologic landscape
• Oral JAK inhibitors have added a fast-acting, non-injectable option to the toolkit, though safety monitoring requirements continue to shape prescribing patterns
• 45+ companies and 50+ molecules are currently active across clinical phases, spanning monoclonal antibodies, small molecules, fusion proteins, and next-generation modalities
• Newer intracellular targets, including TYK2 inhibition and STAT6 degradation, are emerging as attempts to separate efficacy from the off-target effects associated with broader immunosuppression
The net effect: physicians finally have choices, but "more options" hasn't yet translated into a clearly superior standard of care for the hardest-to-treat patients.

Moderate to Severe Atopic Dermatitis report is built to answer questions like, "where do you see the greatest commercial white space in AD - biologics, orals, or topicals?"
Explore now: https://thelansis.com/reports/moderate-to-severe-atopic-dermatitis-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=msad_mo

Treatment Landscape: Momentum, But Not Resolution
Recent regulatory activity underscores how active this space remains:
• Difamilast (Adquey), a topical PDE4 inhibitor, secured approval for mild-to-moderate disease - reinforcing that even the "lighter" end of the spectrum is still innovating
• Zumilokibart reported positive Phase II data with strong EASI-75 response rates versus placebo, keeping the IL-13 pathway commercially relevant even as it crowds
• Not every story has been positive: safety signals around malignancy risk have disrupted at least one anti-OX40 program and raised questions for an amlitelimab-class asset, a reminder that mechanism novelty alone doesn't guarantee a clean path to launch

For senior leaders, the takeaway is nuanced: pipeline density is high, but pipeline differentiation is still scarce. Most late-stage assets compete on modest efficacy deltas and convenience (dosing frequency, oral vs. injectable) rather than transformative outcomes.

Unmet Medical Need: Where the Gaps Still Bite
Despite the influx of biologics and orals, several unmet needs persist and continue to shape KOL and payer expectations:
• Durability of response - many patients see efficacy plateau or relapse, and long-term remission (not just symptom control) remains elusive
• Itch and sleep burden - itch is often under-addressed by therapies optimized primarily for skin clearance (EASI/IGA), even though it is what patients rank as most disruptive
• Pediatric and adolescent access - label expansion into younger populations continues to lag behind adult approvals
• Safety-efficacy trade-offs - clinicians are increasingly weighing malignancy and cardiovascular signals against incremental efficacy gains, complicating first-line positioning
• Precision selection - there is no validated biomarker yet to match patients to the right mechanism upfront, forcing a trial-and-error approach that frustrates both physicians and patients

This is precisely the gap that shapes a differentiated TPP, and where the next wave of commercial value is likely to be created.

Worth Reflecting On
If your organization is developing (or licensing) an AD asset, does your current TPP address durability and itch control, or does it just chase the next EASI-75 headline?

Our latest report on Moderate to Severe Atopic Dermatitis breaks down exactly this: emerging therapy profiling, TPP benchmarking against approved and pipeline assets, and unmet-need mapping across the 8 Major Markets: https://thelansis.com/reports/moderate-to-severe-atopic-dermatitis-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=msad_mo

TPP Insights: What "Differentiated" Actually Looks Like in 2026
Based on the current competitive set, a commercially defensible TPP for AD increasingly needs to demonstrate:
• A clear efficacy edge on itch/quality-of-life endpoints, not just skin-clearance scores
• A credible long-term safety database, particularly around malignancy and cardiovascular risk, given recent setbacks in the class
• Dosing convenience - oral, less-frequent injectable, or combination regimens that reduce treatment burden
• A pathway into underserved segments (pediatric, biologic-experienced/inadequate-responder populations)
• Positioning that supports favorable payer conversations in an increasingly biosimilar- and generic-adjacent landscape

Assets that check even two or three of these boxes are the ones most likely to command premium positioning through the 2026-2036 forecast window.

The Bigger Picture
The moderate-to-severe AD market is no longer short on innovation, it's short on resolution. The next five years will likely reward companies that solve for durability, itch, and safety simultaneously, rather than those simply adding another IL-4/IL-13 or JAK entrant to an already-full shelf.

Thelansis's 2026 Moderate to Severe Atopic Dermatitis report was built for exactly this kind of decision-making, combining primary KOL research, competitive intelligence, and TPP analysis into a single, decision-ready view of the emerging landscape. Learn more: https://thelansis.com/reports/moderate-to-severe-atopic-dermatitis-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=msad_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.